(MENAFN- PR Newswire) VALENCIA, Spain, April 3, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced its participation in the 23rd
Annual
Needham Virtual Healthcare Conference, being held in a virtual format, April 8-11, 2024. Company management will meet with investors in one-on-one meetings during the conference. About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiRTM trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain.
For more information, please visit
and engage with us on LinkedIn.
| Company Contact.
| Investor and Media Contact |
| Frédéric Legros
| Amy Conrad |
| Executive Chairman and CEO | Juniper Point |
| [email protected]
| [email protected] |
| +33679495790 | +1 858-366-3243 |
SOURCE ARTHEx Biotech
MENAFN03042024003732001241ID1108052404
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.